ALAMEDA, Calif. & JERUSALEM--(BUSINESS WIRE)--BioTime, Inc. (NYSE MKT: BTX), HBL Hadasit Bio-Holdings Ltd. (Tel Aviv Stock Exchange: HDST) and Cell Cure Neurosciences Ltd. (Cell Cure) today announced that Cell Cure has received the final results of a series of extensive preclinical safety and efficacy studies of its development-stage product designated OpRegen®, which is intended for use in the treatment of dry form age-related macular degeneration (dry-AMD). These studies were conducted by Cell Cure and contract research organizations in preparation for an IND filing with the Food and Drug Administration for a Phase 1/2a study in patients with geographic atrophy, the severe stage of dry-AMD. OpRegen® consists of retinal pigment epithelial cells derived from human embryonic stem cells using a proprietary directed differentiation method. OpRegen® is intended to be administered into the subretinal space of patients as a suspension of cells to treat this leading cause of blindness.
Help employers find you! Check out all the jobs and post your resume.
